SCHEMBL7817253

SCHEMBL7817253

COc1cc(C2C3=C(CC(C)(C)CC3=O)NC3=C2C(=O)CC(C)(C)C3)ccc1O

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 11/20 0.76
ALDH1A1 P00352 6/20 0.76
KDM4E B2RXH2 9/20 0.75
HTT P42858 2/20 0.72
TSHR P16473 1/20 0.72
HPGD P15428 2/20 0.67
HSD17B10 Q99714 2/20 0.67
MEN1 O00255 1/20 0.62
CASP1 P29466 1/20 0.62
CASP7 P55210 1/20 0.62
KMT2A Q03164 1/20 0.62
RAD52 P43351 1/20 0.59
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.56
ALOX15 P16050 1/20 0.54
NPC1 O15118 1/20 0.53
GPR174 Q9BXC1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12135872 0.86 KDM4E (0.74) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL15057001 0.86 ALDH1A1 (0.57) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL10046487 0.84 GAA (0.73) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL15056854 0.83 GAA (0.78) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL30545905 0.81 GPR174 (0.75) GAAALDH1A1KDM4EHTTHSD17B10
SCHEMBL7820721 0.81 GPR174 (0.75) GAAALDH1A1KDM4EHTTHSD17B10
SCHEMBL15056340 0.81 GAA (0.69) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL3324154 0.79 KDM4E (0.75) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL15057460 0.79 GAA (0.72) GAAALDH1A1KDM4EHTTTSHR
SCHEMBL7817352 0.79 MAPT (0.71) GAAALDH1A1KDM4EHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794572-B1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMÉTIQUE (FR) 2016-08-03 EP claimed
US-20140348768-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMETIQUE (FR) 2014-11-27 US claimed
EP-2794572-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN Pierre Fabre Dermo-Cosmétique (FR) 2014-10-29 EP claimed
WO-2013093019-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-06-27 WO claimed
US-6265127-B1 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers EASTMAN KODAK COMPANY 2001-07-24 US claimed
US-9493421-B2 Acridinedione derivatives for treating pigmentation disorders and ageing of the skin PIERRE FABRE DERMO COSMETIQUE (FR) 2016-11-15 US disclosed
US-9493421-B2 Acridinedione derivatives for treating pigmentation disorders and ageing of the skin PIERRE FABRE DERMO COSMETIQUE (FR) 2016-11-15 US disclosed
US-9493421-B2 Acridinedione derivatives for treating pigmentation disorders and ageing of the skin PIERRE FABRE DERMO COSMETIQUE (FR) 2016-11-15 US disclosed
EP-2794572-B1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMÉTIQUE (FR) 2016-08-03 EP disclosed
EP-2794572-B1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMÉTIQUE (FR) 2016-08-03 EP disclosed
US-20140348768-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMETIQUE (FR) 2014-11-27 US disclosed
US-20140348768-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMETIQUE (FR) 2014-11-27 US disclosed
US-20140348768-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO COSMETIQUE (FR) 2014-11-27 US disclosed
EP-2794572-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN Pierre Fabre Dermo-Cosmétique (FR) 2014-10-29 EP disclosed
WO-2013093019-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-06-27 WO disclosed
WO-2013093019-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-06-27 WO disclosed
US-6265127-B1 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers EASTMAN KODAK COMPANY 2001-07-24 US disclosed
EP-1109070-A2 1,4-Dihydropyridine charge control agents for electrostatographic toners and developers EASTMAN KODAK COMPANY (US) 2001-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140348768-A1 ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN TYR, PAH, AKR1C3 GAA 2692/4885ALDH1A1 118/4885KDM4E 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.